1Elevan Bio

1Elevan Bio is a private, pre-revenue biotech firm founded in 2021, developing and delivering peptide-based therapeutics. The company's strategy centers on utilizing existing FDA-approved peptides and pursuing expanded access pathways to address chronic diseases across multiple specialties including endocrinology, cardiology, and oncology. With operations launching in Spring 2026, 1Elevan is positioning itself at the intersection of advanced peptide science and patient-centric therapeutic delivery, aiming to shift treatment paradigms away from traditional small-molecule drugs.

Focus on advanced application and delivery of existing FDA-approved peptides, potentially involving novel delivery systems and FDA-expanded-access pathways to create precision therapies.

1Elevan Bio competes with large pharmaceutical companies and biotechs developing novel peptide drugs, as well as compounding pharmacies and telehealth providers offering peptide therapies. Its differentiation hinges on a specialized focus on FDA pathways and advanced delivery systems for approved peptides.